为明确胃肠道原发NHL特别是MALT淋巴瘤的发病特征及组织学起源,本研究使用LN_(1～3)系列抗体对34例胃肠道原发NHL进行免疫组化检测。结果显示:34例中MALT淋巴瘤5例(14.7％),其中3例由滤泡中心细胞样细胞构成,另2例由中心母细胞样细胞构...为明确胃肠道原发NHL特别是MALT淋巴瘤的发病特征及组织学起源,本研究使用LN_(1～3)系列抗体对34例胃肠道原发NHL进行免疫组化检测。结果显示:34例中MALT淋巴瘤5例(14.7％),其中3例由滤泡中心细胞样细胞构成,另2例由中心母细胞样细胞构成。肿瘤细胞在LN_1显示核周边点状阳性,LN_2显示核膜线状阳性,与正常肠道Peyet板僧帽带处的Marginal zone cell具有相似的形态及染色特性,提示MALT淋巴瘤可能来源于Marginal zone cells。展开更多
目的探讨程序性死亡受体1(PD1)及半胱氨酸天门冬氨酰蛋白酶(cysteine aspartyl protease,Caspasee)募集域家族成员11(caspase recruitment domain family member 11,CARD11)表达与弥漫大B细胞淋巴瘤(DLBCL)患者远期生存的关系。方法选取...目的探讨程序性死亡受体1(PD1)及半胱氨酸天门冬氨酰蛋白酶(cysteine aspartyl protease,Caspasee)募集域家族成员11(caspase recruitment domain family member 11,CARD11)表达与弥漫大B细胞淋巴瘤(DLBCL)患者远期生存的关系。方法选取2012年2月-2014年12月期间唐山市人民医院收治DLBCL患者80例作为本文研究对象,免疫组化法检测淋巴结病理组织PD1和CARD11,分析二者与临床病理参数的关系,采用单因素和多因素Cox回归模型,探讨PD1和CARD11与DLBCL患者远期生存的关系。结果80例DLBCL患者中CARD11阳性为52例,阳性率为65.00%;PD1阳性为44例,阳性率为55.00%;DLBCL患者五年生存率与年龄、Ann Arbor分期、临床疗效、结外累及数目、国际预后指数(IPI)评分、B症状、病理亚型、PD1表达和CARD11表达均有统计学差异(P<0.05);Cox回归分析结果显示Ann-Arbor分期(Ⅲ~Ⅳ)(OR=1.351,95%CI:1.081~1.690)、临床疗效(无效)(OR=1.972,95%CI:1.029~3.780)、年龄(>60岁)(OR=1.473,95%CI:1.182~1.834)、PD1阳性表达(OR=2.399,95%CI:1.892~3.041)和CARD11阳性表达(OR=2.010,95%CI:1.435~2.815)是DLB⁃CL患者5年生存率的独立危险因素(P<0.05)。结论PD1和CARD11均在DLBCL淋巴结病理组织中表达,且是远期生存的独立危险因素,可作为DLBCL患者预后评估有效指标。展开更多
目的研究PET/CT诊断结外淋巴瘤的临床应用价值。方法应用G EDiscovery LS PET/CT扫描机,对42例淋巴瘤患者进行18F-F D G代谢显像,对其中15例(非霍奇金淋巴瘤non Hodgkin lympooma,NHL,13例,霍奇金淋巴瘤Hodgkin lympooma,H L,2例)原发和...目的研究PET/CT诊断结外淋巴瘤的临床应用价值。方法应用G EDiscovery LS PET/CT扫描机,对42例淋巴瘤患者进行18F-F D G代谢显像,对其中15例(非霍奇金淋巴瘤non Hodgkin lympooma,NHL,13例,霍奇金淋巴瘤Hodgkin lympooma,H L,2例)原发和/或继发结外淋巴瘤的显像结果进行定性和半定量分析,并与C T扫描结果进行比较,病理学诊断为金标准。结果PET/CT代谢显像发现15例结外淋巴瘤中20个18F-F D G摄取异常增高病灶,其对结外淋巴瘤病灶的探测的P E T/C T显像灵敏度、特异性、准确率分别为90%、100%、91%;CT显像检出9个真阳性病灶,2个真阴性病灶,灵敏度、特异性、准确率分别为35%、100%、41%。CT与PET/CT检查的一致性为45%。结论PET/CT18F-F D G代谢显像对结外淋巴瘤具有重要的临床诊断价值。展开更多
Gastric B-cell lymphoma of the mucosa associated lym-phoid tissue(MALT) lymphoma is one of the most com-mon forms of extranodal lymphoma.In addition to in-fection with Helicobacter pylori(H.pylori),the presence of an ...Gastric B-cell lymphoma of the mucosa associated lym-phoid tissue(MALT) lymphoma is one of the most com-mon forms of extranodal lymphoma.In addition to in-fection with Helicobacter pylori(H.pylori),the presence of an underlying autoimmune disease has also been associated with MALT lymphoma development.To date,no familial predisposition for MALT lymphomas has been reported as opposed to other types of lymphoma.A 65-year-old woman was admitted at our institution in 1998 with a diagnosis of H.pylori positive gastric MALT lymphoma and the presence of chronic autoim-mune thyroiditis was established on further work-up.H.pylori eradication did not result in regression of the lymphoma and RT-PCR showed the presence of the t(11;18)(q21;q21) translocation.About 1.5 years after H.pylori eradication,chemotherapy with cladribine resulted in complete remission.Due to lymphoma re-currence 13 mo later,radiotherapy to the stomach(46 Gy) resulted in minimal residual disease without further progression.The patient developed a second malig-nancy(Epstein-Bar virus-associated anaplastic large cell lymphoma in the mediastinum) in 2004 which initially responded to two courses of chemotherapy,but she re-fused further therapy and died of progressive lympho-ma in 2006.In 2008,her 55 years old daughter with a long standing Sj gren's syndrome was diagnosed with MALT lymphoma of the right parotid,but no evidence of gastric involvement or H.pylori infection was found.Currently,she is alive without therapy and undergoing regular check-ups.To our knowledge,this is the first report of MALT lymphoma in a f irst-degree relative of a patient with gastric MALT lymphoma in the context of two autoimmune diseases without a clearly established familial background.展开更多
A lthough advanced stage aggressive non-Hodgkin'slymphomas and Hodgkin's disease are thought to be che-motherapy-responsive cancers, a considerable number of patients either relapse or never attain a remission...A lthough advanced stage aggressive non-Hodgkin'slymphomas and Hodgkin's disease are thought to be che-motherapy-responsive cancers, a considerable number of patients either relapse or never attain a remission. High-dose therapy(HDT) followed by autologous stem cell transplantation(ASCT) is often the only possibility of cure for most of these patients. However, many controversial issues still remain with respect to HDT/ASCT for lymphomas, including its role for, the optimal timing of transplantation, the best conditioning regimen and the potential use of localized radiotherapy or immunologic methods to decrease post-transplant recurrence. Recently, mainly due to the unavailability of carmustine, several novel conditioning protocols have been clinically developed, with the aim of improving the overall outcome by enhancing the anti-lymphoma effect and, at the same time, by reducing short and long-term toxicity. Furthermore, the better safety profiles of novel approaches would definitively allow patients aged more than 65-70 years to benefit from this therapeutic option. In this review, we will briefly discuss the most relevant and recent data available regarding HDT/ASCT in lymphomas.展开更多
文摘为明确胃肠道原发NHL特别是MALT淋巴瘤的发病特征及组织学起源,本研究使用LN_(1～3)系列抗体对34例胃肠道原发NHL进行免疫组化检测。结果显示:34例中MALT淋巴瘤5例(14.7％),其中3例由滤泡中心细胞样细胞构成,另2例由中心母细胞样细胞构成。肿瘤细胞在LN_1显示核周边点状阳性,LN_2显示核膜线状阳性,与正常肠道Peyet板僧帽带处的Marginal zone cell具有相似的形态及染色特性,提示MALT淋巴瘤可能来源于Marginal zone cells。
文摘目的探讨程序性死亡受体1(PD1)及半胱氨酸天门冬氨酰蛋白酶(cysteine aspartyl protease,Caspasee)募集域家族成员11(caspase recruitment domain family member 11,CARD11)表达与弥漫大B细胞淋巴瘤(DLBCL)患者远期生存的关系。方法选取2012年2月-2014年12月期间唐山市人民医院收治DLBCL患者80例作为本文研究对象,免疫组化法检测淋巴结病理组织PD1和CARD11,分析二者与临床病理参数的关系,采用单因素和多因素Cox回归模型,探讨PD1和CARD11与DLBCL患者远期生存的关系。结果80例DLBCL患者中CARD11阳性为52例,阳性率为65.00%;PD1阳性为44例,阳性率为55.00%;DLBCL患者五年生存率与年龄、Ann Arbor分期、临床疗效、结外累及数目、国际预后指数(IPI)评分、B症状、病理亚型、PD1表达和CARD11表达均有统计学差异(P<0.05);Cox回归分析结果显示Ann-Arbor分期(Ⅲ~Ⅳ)(OR=1.351,95%CI:1.081~1.690)、临床疗效(无效)(OR=1.972,95%CI:1.029~3.780)、年龄(>60岁)(OR=1.473,95%CI:1.182~1.834)、PD1阳性表达(OR=2.399,95%CI:1.892~3.041)和CARD11阳性表达(OR=2.010,95%CI:1.435~2.815)是DLB⁃CL患者5年生存率的独立危险因素(P<0.05)。结论PD1和CARD11均在DLBCL淋巴结病理组织中表达,且是远期生存的独立危险因素,可作为DLBCL患者预后评估有效指标。
文摘目的研究PET/CT诊断结外淋巴瘤的临床应用价值。方法应用G EDiscovery LS PET/CT扫描机,对42例淋巴瘤患者进行18F-F D G代谢显像,对其中15例(非霍奇金淋巴瘤non Hodgkin lympooma,NHL,13例,霍奇金淋巴瘤Hodgkin lympooma,H L,2例)原发和/或继发结外淋巴瘤的显像结果进行定性和半定量分析,并与C T扫描结果进行比较,病理学诊断为金标准。结果PET/CT代谢显像发现15例结外淋巴瘤中20个18F-F D G摄取异常增高病灶,其对结外淋巴瘤病灶的探测的P E T/C T显像灵敏度、特异性、准确率分别为90%、100%、91%;CT显像检出9个真阳性病灶,2个真阴性病灶,灵敏度、特异性、准确率分别为35%、100%、41%。CT与PET/CT检查的一致性为45%。结论PET/CT18F-F D G代谢显像对结外淋巴瘤具有重要的临床诊断价值。
文摘Gastric B-cell lymphoma of the mucosa associated lym-phoid tissue(MALT) lymphoma is one of the most com-mon forms of extranodal lymphoma.In addition to in-fection with Helicobacter pylori(H.pylori),the presence of an underlying autoimmune disease has also been associated with MALT lymphoma development.To date,no familial predisposition for MALT lymphomas has been reported as opposed to other types of lymphoma.A 65-year-old woman was admitted at our institution in 1998 with a diagnosis of H.pylori positive gastric MALT lymphoma and the presence of chronic autoim-mune thyroiditis was established on further work-up.H.pylori eradication did not result in regression of the lymphoma and RT-PCR showed the presence of the t(11;18)(q21;q21) translocation.About 1.5 years after H.pylori eradication,chemotherapy with cladribine resulted in complete remission.Due to lymphoma re-currence 13 mo later,radiotherapy to the stomach(46 Gy) resulted in minimal residual disease without further progression.The patient developed a second malig-nancy(Epstein-Bar virus-associated anaplastic large cell lymphoma in the mediastinum) in 2004 which initially responded to two courses of chemotherapy,but she re-fused further therapy and died of progressive lympho-ma in 2006.In 2008,her 55 years old daughter with a long standing Sj gren's syndrome was diagnosed with MALT lymphoma of the right parotid,but no evidence of gastric involvement or H.pylori infection was found.Currently,she is alive without therapy and undergoing regular check-ups.To our knowledge,this is the first report of MALT lymphoma in a f irst-degree relative of a patient with gastric MALT lymphoma in the context of two autoimmune diseases without a clearly established familial background.
文摘A lthough advanced stage aggressive non-Hodgkin'slymphomas and Hodgkin's disease are thought to be che-motherapy-responsive cancers, a considerable number of patients either relapse or never attain a remission. High-dose therapy(HDT) followed by autologous stem cell transplantation(ASCT) is often the only possibility of cure for most of these patients. However, many controversial issues still remain with respect to HDT/ASCT for lymphomas, including its role for, the optimal timing of transplantation, the best conditioning regimen and the potential use of localized radiotherapy or immunologic methods to decrease post-transplant recurrence. Recently, mainly due to the unavailability of carmustine, several novel conditioning protocols have been clinically developed, with the aim of improving the overall outcome by enhancing the anti-lymphoma effect and, at the same time, by reducing short and long-term toxicity. Furthermore, the better safety profiles of novel approaches would definitively allow patients aged more than 65-70 years to benefit from this therapeutic option. In this review, we will briefly discuss the most relevant and recent data available regarding HDT/ASCT in lymphomas.
